FDA advisory record · O-051
FDA peptide compounding vote: what the July 2026 recommendation means
Six peptide-related substances received a positive committee recommendation. The votes were advice to FDA. They did not approve medicines, establish safety or effectiveness, change UK law or authenticate an online vial.
The FDA’s Pharmacy Compounding Advisory Committee recommended six of seven peptide-related bulk drug substances for possible inclusion on the section 503A Bulks List in July 2026.
The votes were advisory. They did not approve the substances as medicines or by themselves alter the conditions under which a US pharmacy may compound them.
Written by: Yianni Kiromitis, BSc (Hons) Radiography, PgC Medical Ultrasound (General Imaging), HCPC RA38415. Sources and status checked: 11 August 2026.
What the committee considered
The meeting asked a compounding-list question, not a medicine-approval question.
PCAC met on 23 and 24 July 2026 to advise FDA on whether seven nominated bulk drug substances should be included on the section 503A Bulks List. The meeting covered the free-base and acetate forms of each substance. FDA’s meeting page and materials identify the substances and the uses assessed.
Section 503A is part of US federal law governing pharmacy compounding. It is not a route for approving a new drug. FDA explains that a bulk substance may be used under section 503A only through one of the applicable routes, and that inclusion on the Bulks List is subject to regulatory action and other statutory conditions. Its section 503A overview describes the list, interim categories and enforcement policy.
Which six substances received a positive recommendation?
The use column records the question FDA evaluated. It is not an approved indication.
| Substance considered | Use FDA evaluated | Committee recommendation | What the result establishes |
|---|---|---|---|
| BPC-157 | Ulcerative colitis | Recommend inclusion | Advice on a compounding-list question, not approval or proof of benefit. |
| KPV | Wound healing and inflammatory conditions | Recommend inclusion | Advice to FDA, not proof that marketed KPV products are authentic or effective. |
| TB-500 | Wound healing | Recommend inclusion | Advice to FDA, not authorisation of TB-500 as a medicine. |
| MOTS-c | Obesity and osteoporosis | Recommend inclusion | Advice to FDA. It does not replace the underlying evidence review. |
| Semax | Cerebral ischaemia, migraine and trigeminal neuralgia | Recommend inclusion | Advice limited to the nominated substance and assessed uses. |
| Epitalon | Insomnia | Recommend inclusion | Advice to FDA, not an anti-ageing claim or medicine approval. |
| Emideltide, also called DSIP | Opioid withdrawal, chronic insomnia and narcolepsy | Recommend against inclusion | Advice against inclusion, not a universal prohibition in every country or setting. |
The result is supported by contemporaneous reporting while FDA’s meeting page supplies the agenda, voting questions and briefing record. We will replace the secondary vote source if FDA publishes official minutes with the result.
What changed after the vote?
The advisory record changed. FDA now has formal committee recommendations to consider when it decides how to handle these substances. The meeting also placed the disagreement between FDA staff and a majority of committee members on the public record.
FDA’s introductory briefing document proposed not adding any of the 14 free-base and acetate forms under review. Staff assessed physicochemical characterisation, safety, effectiveness and historical compounding use. The committee reached a different recommendation for six of the seven substance groups.
The practical status remains two separate statements: PCAC recommended that FDA include six substance groups; FDA still controls the formal outcome through the applicable process.
Category status needs careful wording. FDA’s current 503A categories document, updated 14 May 2026, does not list the seven substances in Category 2. Its safety page retains historical summaries for withdrawn nominations. Removal from Category 2 is not the same as placement in Category 1, addition to the 503A Bulks List or approval of a medicine.
What the vote did not change
It did not approve a medicine
FDA drug approval evaluates a defined product, formulation, manufacturing package, indication, population, dosing information and body of evidence. A 503A Bulks List recommendation asks a different question. The committee did not approve any branded or unbranded peptide product.
It did not establish safety or effectiveness
A regulatory recommendation is not a clinical trial. It does not add participants, outcomes, follow-up or adverse-event data to the scientific record. Historical FDA safety analyses also do not disappear because category or nomination status changes.
It did not authenticate an online vial
The vote says nothing about the identity, quantity, purity, sterility or provenance of a product sold online. A label is a claim. A certificate reports what a document says. A test applies to the sample examined. Clinical evidence applies to the intervention and question studied.
It did not create an immediate compounding right
US compounding law contains statutory conditions, list and category mechanisms, enforcement policies and state-law requirements. A pharmacy, clinician or patient who needs the operative US position should consult current FDA material and qualified US advice.
Why FDA staff and the committee could reach different conclusions
Advisory committees hear presentations, discuss evidence and give recommendations. FDA staff prepare scientific and regulatory reviews for the agency. The groups can weigh uncertainty or the statutory criteria differently. Their disagreement does not mean one side conducted a drug-approval review and the other overturned it.
The useful question is narrower: what evidence supported each claim, what limitations remained, and how did each participant apply the 503A criteria? That is why we keep the claim-level evidence record separate from the regulatory update. A vote can alter a process status without altering a clinical verdict.
What this means for readers in the UK
The meeting was a US federal advisory process. It did not grant a UK marketing authorisation, amend the Human Medicines Regulations 2012 or change an MHRA decision.
In the UK, an authorised medicine can be checked through the MHRA product information service. Unlicensed medicines may be supplied in limited circumstances to meet an individual patient’s special clinical need, but this is not an alternative marketing-authorisation route.
“Available from a US compounder”, if that later becomes true under a specific route, would not mean “authorised in the UK”. It would also say nothing about an online seller using a “research use only” label while making human-use claims.
Use the UK regulation of experimental peptide products for the standing UK framework.
Editorial experience
From our editorial process: why we record the vote without changing an evidence verdict
What’s in the Vial? keeps regulatory status, product testing and scientific evidence as separate fields. We use that separation when an event is important but does not answer the reader’s underlying health question.
For this update, we record the meeting date, substances, assessed uses, direction of each recommendation and the fact that FDA retains the final decision. We do not translate a recommendation into “approved”, “safe”, “effective” or “legal everywhere”. We also do not move a compound’s clinical-evidence verdict merely because an advisory committee considered a compounding-list nomination.
A BPC-157 vote cannot identify a vial sold as BPC-157. It cannot show that the vial is sterile. It cannot establish that a person with a different condition would benefit. It cannot transfer a US process outcome to the UK. Each claim needs its own source and review.
We will update this record when FDA publishes a formal outcome. If that changes a compound’s US regulatory status, we will update the affected profile and add a dated entry to the corrections and change log. A clinical verdict will change only if the evidence supporting that exact claim changes.
What should happen next?
FDA can consider the committee’s recommendations alongside staff reviews, public comments and other evidence. A formal outcome may appear through an updated list, policy, notice-and-comment rulemaking or another operative agency record.
Until then, “recommended by PCAC in July 2026” is the accurate status.
Frequently asked questions
Did the FDA approve BPC-157 in July 2026?
No. PCAC recommended that BPC-157-related bulk substances be included on the section 503A Bulks List. This was advice about a compounding question, not medicine approval or proof that a product is safe, effective or authentic.
Can US pharmacies compound the six substances now?
Not because of the vote alone. The operative answer depends on FDA’s current lists, policies, federal conditions and relevant state law. No formal FDA outcome was identified in our 11 August 2026 check.
Which substance received a negative recommendation?
The committee recommended against including emideltide, also known as DSIP, for the uses FDA evaluated. This should not be described as a worldwide ban.
Does the recommendation mean the six substances work?
No. The vote does not add clinical evidence or establish a favourable benefit-risk balance for a marketed medicine. Evidence must still be judged claim by claim.
Did the vote change UK law?
No. A US advisory committee cannot grant a UK marketing authorisation or amend UK medicines law.
When will this page change again?
We check FDA sources monthly and will update sooner if the agency publishes a formal decision, list change, rule or revised safety communication.
Sources checked on 11 August 2026
Primary FDA and UK records define the process and status. Secondary reporting is used only for the committee result while official minutes remain unavailable.
| Source | Type | What it establishes |
|---|---|---|
| FDA meeting page and materials | Primary | Dates, substances, reviewed uses, advisory status and briefing documents. |
| FDA voting questions | Primary | The exact list question for each free-base and acetate form. |
| FDA introductory briefing document | Primary | Staff proposals, withdrawn nominations and the pending final determination. |
| FDA current 503A category document | Primary | The current interim category lists, updated 14 May 2026. |
| FDA section 503A overview | Primary | Conditions, list development and interim policy. |
| Reuters meeting report, 24 July 2026 | Secondary | The recorded six-positive, one-negative committee outcome. |
| Health.com peptide-risk overview, 18 August 2026 | Secondary | Contextual media coverage linking the committee discussion with newer product-quality and human-factors research. Added 19 August 2026; not used to establish the FDA decision or UK law. |
| MHRA unlicensed medicines guidance | Primary UK | The special-clinical-need route and its limits. |